| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Keros Therapeutics, Inc.$11.8
-0.23 (-1.91%)
D 30Pipeline Score Richly Valued Pharma · Commercial
Market Cap
221.47 M
EPS
-3.01
P/E Ratio
-
Value Trade
2.00 M
SEC Financials
Q1 2026Dilution Risk
Revenue
32.00 K
R&D Expenses
16.10 M
Operating CF
-3.53 M
Total Assets
312.29 M
Total Liabilities
26.66 M
Equity
285.63 M
D/E Ratio
12,345
4 %
Week
-1.24 %
1 Month
-31.6 %
3 Month
-33.39 %
6 Month
-78.02 %
5 Year
-46.33 %
All Time
Cash Data
Cash Position
281.50 M
Monthly Burn
1.18 M
Runway
237.7 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
259.08 K
52 Week Range
9.79 - 22.55
% held by Insiders
8.27 %
% held by Institutions
90.78 %
Enterprise Value
-43.72 M
Total Shares
19.79 M
Short %
7.75 %
Float Shares
18.42 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Keros Therapeutics, Inc.
346Total events
2Upcoming
50Tier-1 (high impact)
2019 – 2028Coverage
Upcoming catalysts 2
Event history 344
Jun 8, 2026
◆Oral PresentationPresentation
Participation at Goldman Sachs 47th Annual Global Healthcare Conference
Mar 9, 2026
▲Partnership / LicenserinvaterceptCorporate
Collaboration with MGH for Phase 2 trial design in ALS MyMatch program
amyotrophic lateral sclerosissource ↗
Mar 9, 2026
◆Oral PresentationrinvaterceptPresentation
Presented additional data from Phase 1 trial of rinvatercept at 2026 MDA Clinical & Scientific Conference
neuromuscular diseasessource ↗
Mar 9, 2026
◆Poster PresentationrinvaterceptPresentation
Preclinical presentation: KER-065 Improved Muscle and Bone Mass and Strength in D2.mdx Mouse Model of DMD
Duchenne muscular dystrophysource ↗
Feb 25, 2026
2026
◆Trial InitiationrinvaterceptTrial
Initiate Phase 2 clinical trial of rinvatercept in DMD
Duchenne muscular dystrophysource ↗
Drug Pipeline Intelligence
D30
Pipeline Score $28M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.1x
rNPV / MCap Top 35%
Micro Cap (rank 593 of 911)
Percentile RankKeros Therapeutics, Inc. faces pipeline headwinds (30/100), with $221M risk-adjusted pipeline value, led by Dose A KER-012 in Pulmonary Arterial Hypertension (Phase 2).
Showing 0 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
rinvatercept | neuromuscular diseases, specifically Duchenne muscular dystrophy and amyotrophic lateral sclerosis | Phase 1 | 2026-03-09 | increase in muscle mass; decrease in fat mass; increase in bone mineral density Read More | Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference Read More | |
rinvatercept | neuromuscular diseases, specifically Duchenne muscular dystrophy and amyotrophic lateral sclerosis | Phase 1 | 2026-03-09 | increase in muscle mass; decrease in fat mass; increase in bone mineral density Read More | Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference Read More | |
rinvatercept | neuromuscular diseases, specifically Duchenne muscular dystrophy and amyotrophic lateral sclerosis | Phase 1 | 2026-03-09 | increase in muscle mass; decrease in fat mass; increase in bone mineral density Read More | Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in KROS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
KROS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
KROS▲ +5.6%on this news
Keros Therapeutics Appoints Anne Prener to its Board of Directors
Keros Therapeutics has appointed Dr. Anne Prener to its Board of Directors, effective July 1, 2026. Dr. Prener brings significant clinical development and executive leadership experience, which Keros believes will support its corporate strategy and long-term growth. The company aims to address significant unmet patient needs through its innovative therapeutics.
Read more →KROSKeros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference
Keros Therapeutics announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference, scheduled for June 8, 2026. CEO Jasbir S. Seehra will present in a fireside chat format. The event will be accessible via a live audio webcast and archived replay on Keros' website. Keros is focused on developing therapeutics targeting TGF-β signaling disorders.
Read more →KROS▼ -8.3%on this news
Keros Therapeutics Reports Recent First Quarter 2026 Financial Results
Keros Therapeutics reported its financial results for Q1 2026, showing a net loss of $23.7 million compared to a net income of $148.5 million in Q1 2025. The decrease was attributed to reduced revenue from a license agreement with Takeda and lower R&D expenses due to corporate restructuring. Keros is optimistic about advancing its pipeline, particularly with elritercept entering Phase 3 trials for myelofibrosis-related anemia.
Read more →KROSKeros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference
Keros Therapeutics presented additional data from its Phase 1 trial of rinvatercept at the 2026 MDA Conference. The data highlighted the drug's potential in treating neuromuscular diseases like Duchenne muscular dystrophy and amyotrophic lateral sclerosis. The trial showed that rinvatercept was well-tolerated, with significant improvements in muscle mass and bone density. Keros plans to advance rinvatercept into Phase 2 trials.
Read more →KROSKeros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS
Keros Therapeutics has partnered with the Sean M. Healey & AMG Center for ALS to design a Phase 2 clinical trial for rinvatercept, targeting patients with ALS. This collaboration is part of the ALS MyMatch program, which utilizes biomarker-driven approaches to match patients with experimental therapies. The initiative aims to enhance treatment options for ALS, a progressive disorder with significant unmet needs.
Read more →KROS▼ -15%on this newsshared move
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Keros Therapeutics reported its financial results for Q4 and full year 2025, highlighting a net income of $87 million and a reduced net loss compared to the previous year. The company is focusing on advancing its lead product, rinvatercept, into Phase 2 trials for Duchenne muscular dystrophy and engaging regulators for trials in ALS. Despite financial progress, there are concerns regarding increased expenses and a decrease in cash reserves.
Read more →KROSKeros Therapeutics Appoints Charles Newton to its Board of Directors
Keros Therapeutics has appointed Charles Newton to its Board of Directors, effective March 9, 2026. Newton brings substantial expertise in healthcare finance, having held senior roles at several investment banks and biotech companies. His addition is expected to complement the existing skillset of Keros' board, aiding in the advancement of their clinical programs and strategic initiatives. Concurrently, Carl Gordon will step down from the board on the same date, marking a transition in Keros' leadership team.
Read more →KROSKeros Therapeutics Announces Participation at Upcoming Healthcare Conferences
Keros Therapeutics has announced its participation in several healthcare conferences where its President and CEO, Jasbir S. Seehra, Ph.D., will present. The events include the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the TD Cowen 46th Annual Health Care Conference, scheduled for late February and early March 2026, respectively. Archived presentations will be available on the company's website for 90 days after the events. This engagement highlights Keros' focus on developing treatments for disorders related to the transforming growth factor-beta family of proteins.
Read more →KROSKeros Therapeutics Announces Final Results of Tender Offer
Keros Therapeutics announced the final results of its cash tender offer, successfully repurchasing 10,950,165 shares at $17.75 each, totaling approximately $194.4 million. The offer concluded on November 18, 2025, and was part of a broader $375 million capital return initiative. A total of 17,712,262 shares were tendered, leading to a pro rata acceptance rate of about 62.30%. The company will utilize its existing cash for the purchases.
Read more →KROSKeros Therapeutics Announces Preliminary Results of Tender Offer
Keros Therapeutics announced preliminary results of its cash tender offer for up to 10,950,165 shares at $17.75 each, concluding its $375 million capital return program. Approximately 16,659,732 shares were tendered, exceeding the amount Keros intends to repurchase, leading to a pro-rata acceptance of shares. The final number of shares purchased will be confirmed after the guaranteed delivery period. Keros aims to return payment to shareholders promptly following the completion of the transaction.
Read more →KROSKeros Therapeutics Reports Third Quarter 2025 Financial Results
Keros Therapeutics reported its financial results for Q3 2025, highlighting a net loss of $7.3 million, significantly improved from $53.0 million in Q3 2024. The company is advancing its candidate elritercept into a Phase 3 trial for myelodysplastic syndromes, while also preparing for a Phase 2 trial of KER-065 for Duchenne muscular dystrophy. Keros maintains a strong cash position of $693.5 million, expected to fund operations into 2028.
Read more →KROS▲ +9.8%on this news
Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares
Keros Therapeutics has launched a cash tender offer to repurchase up to $194.4 million of its common stock as part of a broader $375 million capital return initiative. The offer, priced at $17.75 per share, will expire on November 18, 2025, unless extended. Shareholders are advised to consider their options carefully and consult with advisors before participating.
Read more →KROSKeros Therapeutics Announces Plan for Return of $375 Million in Excess Capital
Keros Therapeutics has announced a plan to return $375 million in excess capital, including a tender offer to repurchase shares worth $194 million. The company will repurchase shares from ADAR1 Capital Management and Pontifax Venture Capital at $17.75 per share. Additionally, Keros plans to distribute a portion of future proceeds from its agreement with Takeda Pharmaceuticals to stockholders. The company aims to start a Phase 2 trial for KER-065 in early 2026.
Read more →KROSKeros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting
Keros Therapeutics presented additional clinical data for KER-065 at the ASBMR 2025 Annual Meeting. The Phase 1 trial demonstrated that KER-065 was well-tolerated among healthy male volunteers, with no serious adverse events reported. The data highlights KER-065's potential in treating Duchenne muscular dystrophy and its effects on bone health.
Read more →KROSKeros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy
Keros Therapeutics announced that the FDA has granted Orphan Drug designation for KER-065, aimed at treating Duchenne muscular dystrophy (DMD). This designation highlights the significant unmet medical need for DMD patients and offers potential benefits such as market exclusivity. KER-065 is set to enter Phase 2 clinical trials as part of its development.
Read more →KROS▼ -7.3%on this news
Keros to Exclusively Prioritize the Clinical Advancement of KER-065
Keros Therapeutics has announced a strategic shift to prioritize the clinical development of KER-065, discontinuing the development of cibotercept. This decision follows the termination of cibotercept's Phase 2 trial in pulmonary arterial hypertension. The company aims to streamline operations and enhance focus on KER-065, which shows promise for treating Duchenne muscular dystrophy, with a Phase 2 trial expected to start in early 2026.
Read more →KROSKeros Therapeutics Reports Second Quarter 2025 Financial Results
Keros Therapeutics reported its second quarter 2025 financial results, noting a reduction in net loss to $30.7 million, down from $45.3 million in the previous year. The company highlighted its strategic focus on developing novel therapeutics, particularly KER-065, which is slated to enter a Phase 2 clinical trial for Duchenne muscular dystrophy in early 2026. Despite a rise in research and development costs, Keros' cash reserves increased to $690.2 million, enabling its operational plans through 2028. The report also included cautionary forward-looking statements about the potential risks involved.
Read more →KROSKeros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept
Keros Therapeutics has initiated patient dosing in the Phase 3 RENEW clinical trial for elritercept, targeting adults with transfusion-dependent anemia linked to myelodysplastic syndromes (MDS). This milestone triggers a $10 million payment from Takeda, with potential for further financial benefits. The trial aims to assess elritercept's efficacy in reducing red blood cell transfusions.
Read more →KROS▼ -6.3%on this news
Keros Announces Return of $375 Million in Excess Capital to Stockholders
Keros Therapeutics has announced a plan to return $375 million in excess capital to its stockholders following a strategic review. The Board of Directors aims to enhance stockholder value while continuing the development of its lead product candidate, KER-065, for neuromuscular diseases. The specific terms of the capital return are yet to be finalized.
Read more →KROSKeros Therapeutics Announces Participation at Goldman Sachs 46 th Annual Global Healthcare Conference
Keros Therapeutics, a clinical-stage biopharmaceutical company, announced that its CEO, Jasbir S. Seehra, Ph.D., will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025. The event will feature a live audio webcast, allowing investors to access insights on the company's developments. Keros is focused on developing treatments targeting disorders linked to dysfunctional TGF- signaling, including its lead candidate for Duchenne muscular dystrophy.
Read more →KROSKeros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring Discontinues Development of Cibotercept in PAH Announces Corporate Restructuring to Align Operations with Ongoing Strategic Priorities Lexingto
Keros Therapeutics announced the discontinuation of development for its drug cibotercept in pulmonary arterial hypertension (PAH) following safety concerns highlighted during the TROPOS trial. The company halted all dosing as early observations indicated adverse events related to pericardial effusion. A corporate restructuring will reduce its workforce by approximately 45%, expected to yield annualized savings of $17 million. Keros remains committed to its strategic review process and evaluates development strategies for cibotercept in other indications.
Read more →KROSKeros Therapeutics Highlights Commitment to Maximizing Stockholder Value
Keros Therapeutics has filed an investor presentation and issued an open letter to stockholders ahead of its Annual Meeting on June 4, 2025. The company urges stockholders to vote in favor of its director nominees while outlining its commitment to maximizing stockholder value through a strategic review process. Keros highlighted its promising product pipeline, including KER-065 and elritercept, and noted a successful partnership with Takeda that promises significant future funding. However, the ongoing campaign by ADAR1 Capital could pose risks to the company's strategic review and future plans.
Read more →KROSKeros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference
Keros Therapeutics, a clinical-stage biopharmaceutical company, announced that its CEO, Jasbir S. Seehra, will participate in a fireside chat at the Bank of America 2025 Global Healthcare Conference. The event is set for May 13, 2025, and will include a live audio webcast. Keros is known for developing therapeutics targeting disorders linked to dysfunctional TGF- signaling, with several promising candidates in its pipeline.
Read more →KROSKeros Reinforces Commitment to Maximizing Stockholder Value
Keros Therapeutics announced its commitment to maximizing stockholder value through a strategic review process in response to pressure from ADAR1 Capital Management. The Board plans to evaluate several strategic alternatives, including a potential sale or returning capital to stockholders. Keros has a strong financial position, bolstered by a significant deal with Takeda Pharmaceuticals. However, the ongoing conflict with ADAR1 may pose risks to board stability and focus during this critical review period.
Read more →KROS▼ -5.5%on this newsshared move
Keros Therapeutics Reports Recent First Quarter 2025 Financial Results
Keros Therapeutics reported its Q1 2025 financial results, highlighting a notable shift from a net loss to a net income of $148.5 million, primarily due to revenue from its license agreement with Takeda. The company announced positive topline results from the Phase 1 trial of KER-065 and plans to advance it to Phase 2 by Q1 2026. However, Keros is also facing increased research and development expenses and is undergoing a strategic review to enhance shareholder value. Despite these challenges, the company has sufficient cash reserves projected to sustain operations through 2029.
Read more →KROS▲ +18.5%on this news
Keros Therapeutics Announces Review of Strategic Alternatives Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process
Keros Therapeutics has announced a formal review of strategic alternatives aimed at maximizing stockholder value, including a potential sale or continued investment in its pipeline. The Board has also adopted a limited-duration stockholder rights plan in response to significant stock accumulation by potential influencing investors. This plan is designed to ensure fair participation in the strategic review process and protect stockholder interests. Keros will provide an update on the review process within 60 days but has not set a definitive timeline for completion.
Read more →KROS▼ -5.6%on this news
Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers Trial achieved key objectives for safety, tolerability, pharmacokinetics and pharmacodynamics Clinical
Keros Therapeutics has announced initial topline results from its Phase 1 clinical trial of KER-065, which successfully met key objectives regarding safety, tolerability, pharmacokinetics, and pharmacodynamics. The trial demonstrated that KER-065 was generally well-tolerated, with no serious adverse events reported. The data supports the drug's potential impact in treating Duchenne muscular dystrophy (DMD). Keros plans to engage with regulatory authorities and aims to initiate a Phase 2 clinical trial in DMD by the first quarter of 2026.
Read more →KROSKeros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
Keros Therapeutics has reported its fourth quarter and full year 2024 financial results, highlighting a strengthened cash position following a $200 million payment from Takeda Pharmaceuticals. The company plans to advance its pipeline, including KER-065 in neuromuscular disease and cibotercept in pulmonary arterial hypertension. Despite a rise in net losses attributed to heightened research and development efforts, Keros also saw a substantial increase in revenue compared to the prior year, indicating potential for continued growth.
Read more →KROSKeros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference
Keros Therapeutics, a clinical-stage biopharmaceutical company, announced that its CEO, Jasbir S. Seehra, Ph.D., will present at the Guggenheim SMID Cap Biotech Conference on February 6, 2025. The company focuses on developing therapeutics for disorders related to TGF- family proteins. Key product candidates include cibotercept for pulmonary arterial hypertension and elritercept for cytopenias in patients with myelodysplastic syndrome. A live audio webcast of the presentation will be available, with an archived replay accessible afterward.
Read more →KROSKEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Keros Therapeutics, Inc. on Behalf of Keros Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is conducting an investigation into Keros Therapeutics, Inc. on behalf of its stockholders, amidst concerns of possible violations of federal securities laws. This action follows Keros's decision to halt dosing in the TROPOS trial due to safety concerns related to pericardial effusion events. The stock price for Keros plummeted on the news of this halt, raising concerns among investors regarding the company's business practices and legal compliance.
Read more →KROS▲ +5.1%on this news
Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept
Keros Therapeutics has announced the effectiveness of its global license agreement with Takeda, which became effective on January 16, 2025, after fulfilling regulatory requirements. The agreement will provide Keros with an upfront payment of $200 million to further develop elritercept, a therapeutic aimed at treating low blood cell counts in patients with myelodysplastic syndrome and myelofibrosis. This strategic partnership is positioned to enhance Keros' capabilities in advancing its product portfolio, particularly in disorders linked to dysfunctional signaling of TGF-beta proteins. However, the company also acknowledges various operational risks associated with development and commercialization.
Read more →KROS▼ -16.5%on this newsshared move
Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial
Keros Therapeutics has announced a voluntary halt of all dosing in its Phase 2 TROPOS trial for cibotercept, a treatment for pulmonary arterial hypertension, due to safety concerns over adverse events related to pericardial effusion. This halt impacts both the 1.5 mg/kg and placebo arms, following an earlier suspension of the 3.0 mg/kg and 4.5 mg/kg arms. The company remains committed to patient safety and continues to coordinate with regulatory authorities while monitoring trial participants. Topline data for the entire trial is now expected to be presented in the second quarter of 2025.
Read more →KROS▼ -73.2%on this news
Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial Keros will host an update call and webcast today
Keros Therapeutics has announced a voluntary halt in dosing for two treatment arms of its Phase 2 TROPOS trial involving cibotercept due to safety concerns linked to pericardial effusion adverse events. The trial continues with the 1.5 mg/kg arm unaffected, and the company is collaborating with the FDA and regulatory authorities for further investigation. Keros aims to present topline data by the second quarter of 2025, despite these setbacks.
Read more →KROSKeros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition Elritercept demonstrated a durable transfusion independence in lower-risk my
Keros Therapeutics presented promising clinical data for its drug elritercept at the 66th ASH Annual Meeting, highlighting its ability to achieve durable transfusion independence in patients with lower-risk myelodysplastic syndromes. The median duration of response was reported at 134.1 weeks, with concurrent improvements in quality of life related to fatigue. Additional Phase 2 trial results indicated significant hematological benefits and reductions in spleen volume for patients suffering from myelofibrosis. The company plans to soon commence a Phase 3 clinical trial to further explore elritercept's efficacy in transfusion-dependent anemia.
Read more →KROS▲ +9.8%on this news· ran to +23% by day 3
Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept Keros Therapeutics to receive upfront payment of $200 million and is eligible to receive development, approval and commercial miles
Keros Therapeutics has entered into a global license agreement with Takeda to advance elritercept, a therapeutic for hematologic disorders. Under the agreement, Keros will receive an upfront payment of $200 million and is eligible for additional milestone payments that could exceed $1.1 billion. Takeda will handle the development and commercialization of elritercept outside of certain regions. Elritercept is currently involved in two Phase 2 trials and a Phase 3 trial is expected to begin soon.
Read more →KROS▲ +6.2%on this news
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
Keros Therapeutics reported its recent business highlights and third quarter financial results for 2024. The company successfully completed enrollment in its Phase 2 TROPOS trial ahead of schedule, signaling progress in its clinical executions. Financially, Keros reported a net loss of $53 million, up from $39.4 million in the prior year's quarter, attributed to increased research and development activities. Additionally, Keros' cash position was bolstered through an at-the-market offering, projecting operational funding into the third quarter of 2027.
Read more →KROS▲ +6.2%on this news
Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
Keros Therapeutics, a clinical-stage biopharmaceutical firm, will present at the Guggenheim Healthcare Innovation Conference on November 13, 2024. CEO Jasbir S. Seehra, Ph.D., will participate in a fireside chat, with a live audio webcast available online. The company's focus includes developing novel therapeutics for disorders related to TGF- signaling, such as cytopenias and pulmonary arterial hypertension. Keros's lead candidate, elritercept (KER-050), targets low blood cell counts, while other candidates tackle different conditions.
Read more →KROSKeros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition
Keros Therapeutics, Inc. has announced plans to present three abstracts from its hematology program at the 66th American Society of Hematology Annual Meeting taking place from December 7-10, 2024. The abstracts will include results from ongoing Phase 2 clinical trials of elritercept, which targets lower-risk myelodysplastic syndromes and myelofibrosis. The presentations are anticipated to highlight key findings related to treatment efficacy and improvements in patients' quality of life. Keros is focusing on developing therapies that address diseases linked to dysfunctional TGF-beta signaling.
Read more →KROSKeros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer
Keros Therapeutics has appointed Yung H. Chyung, M.D. as its Chief Medical Officer, effective November 1, 2024. Dr. Chyung, who has extensive experience in the biopharmaceutical industry, will play a critical role as Keros advances its clinical programs, including a Phase 3 trial for elritercept and important data readouts for other candidates expected in 2025. The company aims to provide innovative therapeutics for disorders linked to dysfunctional TGF- signaling.
Read more →KROSKeros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare Conference
Keros Therapeutics has announced an updated time for a fireside chat presentation at the 2024 Cantor Global Healthcare Conference, now scheduled for 8:00 a.m. Eastern time on September 19, 2024. The presentation will feature Keros' CEO, Dr. Jasbir S. Seehra. Keros is dedicated to developing novel therapeutics for disorders linked to dysfunctional TGF-β signaling, with several product candidates addressing significant health issues, including anemia and pulmonary arterial hypertension.
Read more →KROS▲ +5.4%on this news· ran to +17% by day 1
Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial
Keros Therapeutics has announced the closure of screening for the Phase 2 TROPOS trial, evaluating cibotercept for pulmonary arterial hypertension (PAH). The company anticipates completing enrollment by the end of September 2024, with topline data expected in the second quarter of 2025. Keros' leadership expressed gratitude towards investigators and patients, emphasizing the importance of this milestone in advancing treatment options for PAH.
Read more →KROS▼ -6.9%on this news
Keros Therapeutics Reports Second Quarter 2024 Financial Results
Keros Therapeutics reported its financial results for the second quarter of 2024, highlighting both significant operational progress and financial metrics. The company experienced a net loss of $45.3 million, which was higher than the previous year due to increased research expenditures. However, Keros reported positive regulatory updates and strong enrollment figures in its clinical trials, suggesting robust pipeline development. The company also noted an increase in cash reserves, which are expected to support operations into 2027.
Read more →KROS▼ -9.7%on this news
Keros Therapeutics Announces Leadership Updates
Keros Therapeutics has announced leadership changes effective July 1, 2024, including the appointment of Jasbir S. Seehra as Chair of the Board and Christopher Rovaldi as President. This decision aims to enhance the company's strategic focus as it prepares for its first Phase 3 clinical trial of elritercept. The Board expresses confidence in Seehra's capabilities and experience, expecting these updates to lead to more effective development of therapies for patients with unmet medical needs. Keros continues to focus on its novel treatment candidates, including elritercept, cibotercept, and KER-065, targeting various serious medical conditions.
Read more →KROS▼ -9.7%on this news
Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association Elritercept continued to demonstrate a durable transfusion indepe
Keros Therapeutics presented encouraging clinical data for its elritercept (KER-050) program at the 29th Annual Hybrid Congress of the European Hematology Association. The data shows that elritercept can achieve durable transfusion independence and improve patient-reported fatigue in lower-risk myelodysplastic syndromes and offers broader clinical benefits in myelofibrosis. Keros is planning to advance to a registrational Phase 3 clinical trial following positive feedback from the FDA. The results highlight elritercept's potential to impact the treatment landscape for these hematologic conditions.
Read more →KROSKeros Therapeutics to Host a Corporate Update Conference Call and Webcast
Keros Therapeutics, Inc. will host a corporate update conference call and webcast on June 17, 2024. The company received positive feedback from the FDA concerning its KER-050 program for myelodysplastic syndromes, achieving alignment on the Phase 3 trial design. Additionally, Keros continues to progress in its ongoing Phase 2 trial of KER-012 for pulmonary arterial hypertension, expecting enrollment completion later this year.
Read more →KROSKeros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
Keros Therapeutics, a clinical-stage biopharmaceutical company, announced that its CEO, Dr. Jasbir S. Seehra, will participate in a fireside chat at the Goldman Sachs 45th Annual Healthcare Conference on June 10, 2024. This presentation will showcase the company’s commitment to developing novel treatments targeting disorders linked to dysfunctional TGF-beta signaling. Keros is advancing multiple product candidates, including therapies for conditions like anemia, pulmonary arterial hypertension, and obesity. A live audio webcast of the event will be available, with an archived replay for later access.
Read more →KROSKeros Therapeutics Appoints Jean-Jacques Bienaim to its Board of Directors
Keros Therapeutics has appointed Jean-Jacques Bienaim to its Board of Directors, effective June 1, 2024. Bienaim, a seasoned executive from the biotechnology sector, previously served as CEO of BioMarin Pharmaceutical and has a strong background in leadership roles across several companies. His appointment comes at a critical time for Keros as it continues to develop its pipeline of therapeutics targeting disorders related to TGF- signaling. The addition of Bienaim is expected to enhance the company's strategic development.
Read more →KROSKeros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association
Keros Therapeutics announced it will present five abstracts from its KER-050 program at the 29th Annual Congress of the European Hematology Association. Notable presentations include findings from a Phase 2 trial in lower-risk MDS and evidence of cardiovascular benefits associated with elritercept. The Congress will be held both virtually and in person from June 13 through 16, 2024. KER-050 aims to address cytopenias in patients diagnosed with myelodysplastic syndromes and myelofibrosis.
Read more →KROSKeros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
Keros Therapeutics has reported strong progress in its clinical pipeline during the first quarter of 2024, with a focus on upcoming milestones for KER-012 in the treatment of pulmonary arterial hypertension. The company is preparing to update regulatory plans for KER-050, aimed at treating myelodysplastic syndromes, in mid-2024. Despite the advancements, Keros faced a net loss of $43.1 million, which reflects rising operational costs driven by increased research and development activities. Furthermore, the company reported cash reserves of $442.4 million, ensuring operational funding through 2027.
Read more →KROSKeros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes
Keros Therapeutics has announced that its lead candidate, KER-050, has received Fast Track designation from the U.S. FDA for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (MDS). This recognition signifies a pressing need for new therapeutic options in this patient population. The company plans to engage with the FDA to design a Phase 3 clinical trial for KER-050, expected to commence in the first half of the year. However, Keros faces risks, including funding and competition challenges, as it continues its developmental efforts.
Read more →KROSKeros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference
Keros Therapeutics, Inc. announced that its President and CEO, Jasbir S. Seehra, Ph.D., will participate in a fireside chat at the upcoming Leerink Partners 2024 Global Biopharma Conference on March 12, 2024. The event will include a live audio webcast for attendees. Keros is focused on developing novel therapeutics for disorders related to dysfunctional TGF- signaling, which are critical in various tissue functions. The company is advancing several product candidates addressing conditions like anemia, pulmonary arterial hypertension, and obesity.
Read more →KROSKeros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Keros Therapeutics, Inc. has announced its business highlights and financial results for Q4 and the full year of 2023. The company has made significant progress in its clinical trials, notably initiating the Phase 2 trial for KER-012 targeting pulmonary arterial hypertension (PAH) and reporting positive developments for KER-050. Keros has bolstered its financial strength through a recent public offering, providing sufficient funding to support operations through 2027 despite reporting a net loss for the quarter. Anticipated milestones for 2024 include updates on the KER-050 and KER-012 programs, showcasing Keros's continued pipeline advancement.
Read more →KROSKeros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress
Keros Therapeutics, Inc. (Nasdaq: KROS) announced it will present three abstracts from its KER-012 program at the Pulmonary Vascular Research Institute 2024 Annual Congress from January 31 to February 3, 2024. These presentations will focus on the development and effects of KER-012, a novel investigational ligand trap designed to treat pulmonary arterial hypertension. The data presented is expected to provide insights into the therapeutic potential of KER-012, which inhibits signaling linked to cardiovascular disorders. Keros continues to navigate challenges related to funding and competition in the biopharmaceutical landscape.
Read more →KROSKeros Therapeutics Announces Closing of Upsized Public Offering of Common Stock
Keros Therapeutics announced the completion of an upsized public offering, closing on January 8, 2024, which raised approximately $151.3 million. This offering included the sale of 4,025,000 shares of common stock at a price of $40.00 each, with an additional 525,000 shares purchased due to strong demand. The proceeds will enable the company to fund its operational and capital expenses through 2027. Keros specializes in developing novel therapeutics linked to the TGF-β family of proteins, with several product candidates in its pipeline.
Read more →KROS▲ +18.5%on this newsshared move
Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
Keros Therapeutics, a clinical-stage biopharmaceutical company, announced the pricing of an upsized public offering of 3,500,000 shares of common stock at $40.00 each, expected to raise $140 million. Goldman Sachs and other financial institutions are involved as joint book-running managers for this offering. The transaction is scheduled to close on January 8, 2024, pending customary conditions. Keros plans to use the raised funds to support its pipeline of therapeutic developments targeting disorders related to TGF-beta signaling.
Read more →KROSKeros Therapeutics to Develop KER-065 for the Treatment of Obesity
Keros Therapeutics has initiated a Phase 1 clinical trial for KER-065, a novel treatment targeting obesity, aiming to assess its safety and efficacy in healthy volunteers. Preliminary preclinical results suggest that KER-065 could help reduce fat mass while preserving muscle. The company plans to progress to a proof-of-concept trial in obese patients following the Phase 1 study, with initial data anticipated in the first quarter of 2025. However, the outcome of the ongoing trial is uncertain, posing inherent risks to Keros's development plan.
Read more →KROSKeros Therapeutics Announces Proposed Public Offering of Common Stock
Keros Therapeutics has announced a proposed public offering of $120 million in common stock, with all shares being sold by the company. Goldman Sachs, Leerink Partners, Piper Sandler, and Truist Securities will act as underwriters for the offering. This public offering is subject to market conditions, and there is uncertainty regarding its completion and other terms. Keros is focused on developing therapeutics for disorders linked to TGF-β proteins, with multiple product candidates in its pipeline.
Read more →KROSJanuary 2024 Corporate Presentation Corporate Presentation 2 Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Se
Keros Therapeutics has provided a corporate presentation outlining its forward-looking statements regarding product candidates KER-050, KER-012, and KER-065. The presentation emphasizes the potential of these therapies to address conditions such as anemia from myelodysplastic syndromes and obesity without muscle loss. However, the company acknowledges various risks, including its limited operational history and challenges in securing further funding. Additionally, there is competitive pressure from other biotechnology firms working on similar treatments.
Read more →KROS▼ -20.5%on this news
Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition KER-050 (elritercept) achieved durable transfusion independence in lower-risk MD
Keros Therapeutics presented promising clinical data for its KER-050 program at the 65th ASH Annual Meeting, showing that KER-050 achieved durable transfusion independence in lower-risk MDS patients. The drug's treatment was associated with improvements in fatigue and cardiac stress biomarkers, and preliminary findings suggest broader benefits in myelofibrosis cases. The ongoing Phase 2 trials indicate the potential for KER-050 to ameliorate ineffective hematopoiesis and improve the quality of life in difficult-to-treat patient populations.
Read more →KROSKeros Therapeutics to Present at Upcoming Healthcare Conferences
Keros Therapeutics, Inc. will present at two upcoming healthcare conferences, including the Stifel 2023 Healthcare Conference and the Piper Sandler 35th Annual Healthcare Conference. The company aims to share insights on its novel therapeutics targeting disorders linked to dysfunctional TGF- family proteins. CEO Jasbir S. Seehra, Ph.D., will provide a corporate presentation and a fireside chat at these events. Keros focuses on drug development for conditions such as anemia, thrombocytopenia, pulmonary arterial hypertension, and neuromuscular diseases.
Read more →KROSNovember 2023 Corporate Presentation Corporate Presentation 2 Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private S
Keros Therapeutics has provided a corporate presentation highlighting its pipeline and progress in developing drugs KER-050, KER-012, and KER-065 targeting TGF- signaling pathways. The company is currently conducting a Phase 2 clinical trial for KER-050 aimed at treating anemia in patients with Myelodysplastic Syndromes. While Keros has potential for significant therapeutic advancement, it faces challenges such as financial sustainability and competitive pressures from other companies in the biopharma sector. The presentation emphasizes both the optimistic potential of their drugs and the inherent risks of their development process.
Read more →KROSKeros Therapeutics Reports Recent Business Highlights and Third Quarter 2023 Financial Results
Keros Therapeutics has reported significant advancements in its clinical pipeline and financial results for Q3 2023. The company is progressing with Phase 2 trials for KER-050 and KER-012, with upcoming data presentations scheduled for the ASH Annual Meeting. However, it also disclosed a net loss of $39.4 million, an increase attributed to heightened research and development expenses. Additionally, Keros has decided to deprioritize its KER-047 program, indicating strategic shifts in its developmental focus.
Read more →KROSKeros Therapeutics to Present at the 65th American Society of Hematology Annual Meeting and Exposition
Keros Therapeutics, a clinical-stage biopharmaceutical company, has announced that it will present five abstracts at the 65th American Society of Hematology Annual Meeting. The presentations will cover results from ongoing Phase 2 clinical trials of its candidate KER-050, targeting patients with myelodysplastic syndrome and myelofibrosis. The meeting will be held both in-person and virtually from December 9 to 12, 2023. Keros aims to showcase its advancements in treating cytopenias associated with these disorders.
Read more →KROSKeros Therapeutics Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle Society
Keros Therapeutics presented encouraging preclinical data on its KER-065 program at the 28th International Annual Congress of the World Muscle Society. The study demonstrated that RKER-065 significantly improves muscle mass, strength, and bone mineral density in a mouse model of Duchenne muscular dystrophy (DMD). Additionally, RKER-065 counteracts the negative effects of glucocorticoids, which are commonly used in DMD treatment. Keros plans to initiate a Phase 1 clinical trial for KER-065 in healthy volunteers in early 2024.
Read more →KROSKeros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
Keros Therapeutics has provided a business update along with its financial results for the second quarter of 2023, reporting a net loss of $37.5 million. The company highlighted its progression in developing its pipeline, notably with the initiation of a Phase 2 clinical trial for KER-050 and upcoming trials for KER-065 and KER-012. Keros anticipates moving KER-065 into clinical trials for Duchenne muscular dystrophy in early 2024. Despite the financial losses, Keros maintains sufficient cash reserves to support operations through the end of 2025.
Read more →KROSAugust 2023 Corporate Presentation Corporate Presentation 2 Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Sec
Keros Therapeutics presented its corporate update in August 2023, highlighting its forward-looking statements regarding growth and clinical development. The company is progressing with several product candidates, including KER-050, KER-047, KER-012, and KER-065, aimed at addressing various disorders linked to dysfunctional TGF- signaling. However, the presentation noted risks surrounding funding and operational challenges that could impact the timeline and success of its clinical trials. Keros emphasizes the potential of its products to provide disease-modifying benefits to patients with conditions such as Myelodysplastic Syndromes.
Read more →KROSKeros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension Keros Therapeutics announces U.S. Food and Drug
Keros Therapeutics has announced that the U.S. FDA has approved its investigational new drug application to commence a Phase 2 clinical trial of KER-012 for patients with pulmonary arterial hypertension (PAH). The trial, named TROPOS, aims to evaluate the effects of KER-012 on pulmonary hemodynamics and exercise capacity in combination with existing therapies. Keros will provide detailed insights during a conference call on August 8, 2023, bringing attention to the anticipated impact of this treatment on patients with PAH, a condition with significant unmet medical needs.
Read more →KROS▼ -6.6%on this news
Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conference
Keros Therapeutics, a biopharmaceutical company, announced it will not participate in a planned fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on June 14, 2023. This decision comes as the company focuses on the development of novel treatments for patients with significant unmet medical needs in various disorders. Keros is known for its product candidates aimed at addressing cytopenias and functional iron deficiency, among other health issues.
Read more →KROS▼ -10.4%on this news· ran to -21% by day 3shared move
Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 28th Annual Congress of the European Hematology Association Ke
Keros Therapeutics presented promising results from its KER-050 program at the 28th Annual Congress of the EHA, highlighting durable responses in patients with lower-risk myelodysplastic syndromes (MDS). The ongoing Phase 2 clinical trial has shown significant improvements in hematological markers, while the company has expanded its research to evaluate additional cohorts with iron overload. Keros also announced plans to possibly initiate a Phase 3 trial by the end of the year, depending on further data outcomes. Preclinical data for the ALK2 inhibitor program was also discussed, suggesting new treatment avenues for anemia of inflammation.
Read more →KROSKeros Therapeutics to Present at Goldman Sach's 44 th Annual Global Healthcare Conference
Keros Therapeutics, a clinical-stage biopharmaceutical company, announced that its President and CEO, Jasbir S. Seehra, Ph.D., will participate in a fireside chat at Goldman Sachs' 44th Annual Global Healthcare Conference on June 14, 2023. The company specializes in developing treatments for patients suffering from serious hematological, pulmonary, and cardiovascular conditions. A live webcast of the presentation will be accessible, alongside an archived replay for a limited time post-event. Keros continues to advance its clinical pipeline targeting various conditions with high unmet medical needs.
Read more →KROSKeros Therapeutics Presents Preclinical and Clinical Data from its KER-012 Program at the American Thoracic Society International Conference
Keros Therapeutics presented significant findings on its KER-012 program at the ATS 2023 International Conference. The company showcased data indicating changes in cardiac health biomarkers from its Phase 1 trial in healthy post-menopausal women, suggesting potential benefits for patients with pulmonary arterial hypertension (PAH) and cardiovascular diseases. Additionally, preclinical studies demonstrated RKER-012's efficacy in improving left ventricular function and inhibiting dysregulated vascular remodeling in PAH models. The results support the therapeutic promise of KER-012, highlighting its potential role in addressing high unmet medical needs.
Read more →KROSKeros Therapeutics to Present at the 28th Annual Congress of the European Hematology Association
Keros Therapeutics, Inc. announced it will present three abstracts at the 28th Annual Congress of the European Hematology Association (EHA). The presentations will focus on their KER-050 and ALK2 hematology programs, highlighting significant findings related to patient treatments. The conference will take place both virtually and in person from June 8 to June 15, 2023, showing Keros' continued commitment to advancing therapies for hematological disorders.
Read more →KROSKeros Therapeutics Reports Recent Business Highlights and First Quarter 2023 Financial Results
Keros Therapeutics has provided a business update and reported its financial results for the first quarter of 2023. The company is focused on the development of treatments forhematological, pulmonary, and cardiovascular disorders. Keros announced a strengthened cash position, allowing operations to continue into late 2025, alongside upcoming clinical trial data for its candidates KER-050 and KER-012. However, the company experienced an increased net loss compared to the previous year due to rising research and development costs.
Read more →KROSKeros Therapeutics Appoints Alpna Seth, Ph.D., to its Board of Directors
Keros Therapeutics announced the appointment of Alpna Seth, Ph.D., to its Board of Directors, effective May 1, 2023. Dr. Seth has a strong background in drug development and global operations, having served in senior roles at companies such as Nura Bio Inc. and Biogen, Inc. The CEO of Keros expressed excitement regarding her addition to the board, emphasizing its significance during a crucial time for the company as it aims to advance its innovative product candidates for various medical conditions.
Read more →KROS▲ +6.4%on this news
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results
Keros Therapeutics reported both recent business highlights and financial results for Q4 and full year 2022. Despite reporting a net loss of $104.7 million for the year, Keros' cash position remains robust, enabling the company to fund operations until 2025. Keros is focused on advancing its clinical trials for KER-050, KER-047, and KER-012, which target hematological, pulmonary, and cardiovascular disorders. The company aims to complete enrollment in ongoing clinical trials and report additional data in 2023.
Read more →KROSKeros Therapeutics to Present at Cowen’s 43rd Annual Health Care Conference
Keros Therapeutics, a clinical-stage biopharmaceutical company, has announced that its CEO, Jasbir S. Seehra, Ph.D., will present at Cowen's 43rd Annual Health Care Conference on March 8, 2023. The event emphasizes Keros' commitment to showcasing its advancements in developing novel treatments for serious medical conditions. Interested parties can access the live webcast and the subsequent archived session on the company's website.
Read more →KROSKeros Therapeutics to Present at Cowen's 43 rd Annual Health Care Conference
Keros Therapeutics, a clinical-stage biopharmaceutical company, announced that its President and CEO, Jasbir S. Seehra, Ph.D., will present at Cowen's 43rd Annual Health Care Conference on March 8, 2023. The event will be available via a live audio webcast, offering insight into the company's ongoing development of treatments for hematological, pulmonary, and cardiovascular disorders. Keros is recognized for its innovative approaches in addressing unmet medical needs.
Read more →KROSKeros Therapeutics to Present at the SVB Securities Global Biopharma Conference
Keros Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the SVB Securities Global Biopharma Conference. Jasbir S. Seehra, the company's President and CEO, will present during a fireside chat on February 14, 2023. The event aims to highlight Keros' innovative treatments for various medical conditions such as hematological, pulmonary, and cardiovascular disorders. A live audio webcast and archived replay of the presentation will be available for interested parties.
Read more →KROSKeros Therapeutics Presents Clinical Data from its KER-050 and KER-047 Programs and Preclinical Data from its KER-050 and ALK2 Inhibitor Programs at the 64th American Society of Hematology Annual Meeting and Exposition K
Keros Therapeutics Presents Clinical Data from its KER-050 and KER-047 Programs and Preclinical Data from its KER-050 and ALK2 Inhibitor Programs at the 64th American Society of Hematology Annual Meeting and Exposition Keros Therapeutics will be hosting a conference call and web
Read more →KROSKeros Therapeutics Presents Preclinical Data from its KER-012 Program at the American Heart Association 2022 Scientific Sessions
Keros Therapeutics Presents Preclinical Data from its KER-012 Program at the American Heart Association 2022 Scientific Sessions November 7, 2022, 4 01 PM EST LEXINGTON, Mass., Nov. 7, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (Nasdaq KROS), a clinical-stage b
Read more →KROSKeros Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results LEXINGTON, Mass., November 3, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq KROS), a clinical-stage biopharmaceutical company focused on the disc
Read more →KROSKeros Therapeutics to Present at the 64th American Society of Hematology Annual Meeting and Exposition, Including Presenting Data from its Phase 2 Clinical Trials Evaluating KER-050 and KER-047
Keros Therapeutics to Present at the 64th American Society of Hematology Annual Meeting and Exposition, Including Presenting Data from its Phase 2 Clinical Trials Evaluating KER-050 and KER-047 November 3, 2022 at 9 00 AM ET LEXINGTON, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- K
Read more →KROSKeros Therapeutics Presents Additional Clinical Data from its KER-012 Program and Preclinical Data from its KER-050 Program at the American Society of Bone and Mineral Research 2022 Annual Meeting
Keros Therapeutics Presents Additional Clinical Data from its KER-012 Program and Preclinical Data from its KER-050 Program at the American Society of Bone and Mineral Research 2022 Annual Meeting LEXINGTON, Mass., September 12, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc.
Read more →KROSKeros Therapeutics to Present at the American Society for Bone and Mineral Research 2022 Annual Meeting
LEXINGTON, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary,
Read more →KROSKeros Therapeutics to Present at the Morgan Stanley 20 th Annual Global Healthcare Conference
Keros Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference LEXINGTON, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (Nasdaq KROS), a clinical-stage biopharmaceutical company focused on the discovery, development an
Read more →KROSKeros Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results KER-050 data from ongoing Phase 2 study in patients with lower risk myelodysplastic syndromes demonstrated meaningful respon
Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results KER-050 data from ongoing Phase 2 study in patients with lower risk myelodysplastic syndromes demonstrated meaningful responses across both ring sideroblast-positive and non-RS patien
Read more →KROS▼ -5.2%on this news
Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the Pulmonary Hypertension Association International Conference and Scientific Sessions Lexington, Mass.
Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the Pulmonary Hypertension Association International Conference and Scientific Sessions Lexington, Mass. - June 13, 2022 - Keros Therapeutics, Inc. ("Keros" or the "Com
Read more →KROS▼ -5.7%on this newsshared move
Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 27 th Annual Congress of the European Hematology Association K
Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 27th Annual Congress of the European Hematology Association Keros Therapeutics will be hosting a conference call and webc
Read more →KROS▼ -16.6%on this news
Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 in Healthy Volunteers LEXINGTON, Mass.
Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 in Healthy Volunteers LEXINGTON, Mass., - May 18, 2022 - Keros Therapeutics, Inc. ("Keros") (Nasdaq KROS), a clinical-stage biopharmaceutical company focused on th
Read more →KROSKeros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference Lexington, Mass.
Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference Lexington, Mass. - May 17, 2022 - Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq KROS), a clinical-s
Read more →KROSKeros Therapeutics to Present at the 27th Annual Congress of the European Hematology Association
LEXINGTON, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculosk
Read more →KROS▼ -7.2%on this news
Keros Therapeutics Reports First Quarter 2022 Financial Results Lexington, Mass.
Keros Therapeutics Reports First Quarter 2022 Financial Results Lexington, Mass. - May 5, 2022 - Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel tre
Read more →KROS▲ +7.7%on this news
March 2022 Corporate Presentation Disclaimer Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigat
March 2022 Corporate Presentation Disclaimer Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipa
Read more →KROS▲ +7.7%on this news
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results Lexington, Mass.
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results Lexington, Mass. - March 9, 2022 - Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq KROS), a clinical-stage biopharmaceutical company focused on the discovery
Read more →KROSKeros Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference Lexington, Mass.
Keros Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference Lexington, Mass.- February 11, 2022 - Keros Therapeutics, Inc. ("Keros") (Nasdaq KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializatio
Read more →KROS▲ +10.1%on this news
Keros Therapeutics Appoints Christopher Rovaldi as Chief Operating Officer
Keros Therapeutics Appoints Christopher Rovaldi as Chief Operating Officer LEXINGTON, Mass. - January 31, 2022 - Keros Therapeutics, Inc. ("Keros") (Nasdaq KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel trea
Read more →KROS▼ -8.9%on this news
Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual Meeting and Exposit
Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual Meeting and Exposition Keros Therapeutics will be hosting a conference call an
Read more →KROS▼ -8.9%on this news
Keros Therapeutics Announces Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to KER-050 in China Keros Therapeutics to receive potential milestone payments up to $170.5 million, $20 million up
Keros Therapeutics Announces Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to KER-050 in China Keros Therapeutics to receive potential milestone payments up to $170.5 million, $20 million upfront, and tiered royalty payments in the low double digit
Read more →KROS▼ -8.9%on this news
Corrected Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual Meeting a
Corrected Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual Meeting and Exposition Lexington, Mass. - December 13, 2021 - Keros
Read more →KROSKeros Therapeutics to Present at the Piper Sandler 33 rd Annual Virtual Healthcare Conference Lexington, Massachusetts
Keros Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference Lexington, Massachusetts - November 22, 2021 - Keros Therapeutics, Inc. ("Keros") (Nasdaq KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and comm
Read more →KROSKeros Therapeutics Presents Results from a Preclinical Study of RKER-012 at the American Heart Association 2021 Scientific Sessions Lexington, Mass.
Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 at the American Heart Association 2021 Scientific Sessions Lexington, Mass. - November 15, 2021 - Keros Therapeutics, Inc. ("Keros") (Nasdaq KROS), a clinical-stage biopharmaceutical company focused on the
Read more →KROSKeros Therapeutics to Present at the Jefferies Virtual London Healthcare Conference Lexington, Massachusetts
Keros Therapeutics to Present at the Jefferies Virtual London Healthcare Conference Lexington, Massachusetts - November 11, 2021 - Keros Therapeutics, Inc. ("Keros") (Nasdaq KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializa
Read more →KROSKeros Therapeutics to Present Results from a Preclinical Study of RKER-012 at the American Heart Association 2021 Scientific Sessions
LEXINGTON, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculos
Read more →KROS▲ +27.7%on this news· ran to +43% by day 3shared move
Keros Therapeutics to Present at the 63rd American Society of Hematology Annual Meeting and Exposition, Including Presenting Additional Data from its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic Syndromes
LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculos
Read more →KROS▲ +27.7%on this news· ran to +43% by day 3shared move
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results Lexington, Mass.
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results Lexington, Mass. - November 4, 2021 - Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq KROS), a clinical-stage biopharmaceutical company focused on the discovery, developmen
Read more →KROSKeros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension-Associated Bone Loss at the American Society for Bone and Mineral Research 2021 Annual Meeting Lexington, Mass.
Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension-Associated Bone Loss at the American Society for Bone and Mineral Research 2021 Annual Meeting Lexington, Mass. - October 4, 2021 - Keros Therapeutics, Inc. ("Keros") (Nas
Read more →KROSKeros Therapeutics to Participate in Two Upcoming Healthcare Conferences Lexington, Mass.
Keros Therapeutics to Participate in Two Upcoming Healthcare Conferences Lexington, Mass. - September 2, 2021 - Keros Therapeutics, Inc. ("Keros") (Nasdaq KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treat
Read more →KROSKeros Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results Lexington, Mass.
Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results Lexington, Mass. - August 5, 2021 - Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq KROS), a clinical-stage biopharmaceutical company focused on the discovery, development
Read more →KROSKeros Therapeutics Appoints Simon Cooper, M.B.B.S. as Chief Medical Officer
Keros Therapeutics Appoints Simon Cooper, M.B.B.S. as Chief Medical Officer LEXINGTON, Mass. - August 2, 2021 - Keros Therapeutics, Inc. ("Keros") (Nasdaq KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treat
Read more →KROSKeros Therapeutics Announces Preliminary Results from its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic Syndromes LEXINGTON, Mass.
Keros Therapeutics Announces Preliminary Results from its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic Syndromes LEXINGTON, Mass., - June 22, 2021 - Keros Therapeutics, Inc. ("Keros") (Nasdaq KROS), a clinical-stage biopharmaceutical company focused
Read more →KROSKeros Therapeutics Presents Preclinical Data from ALK2 and KER-050 Hematology Programs at the European Hematology Association EHA2021 Virtual Congress Multiple poster presentations demonstrate that ALK2 inhibition lowere
Keros Therapeutics Presents Preclinical Data from ALK2 and KER-050 Hematology Programs at the European Hematology Association EHA2021 Virtual Congress Multiple poster presentations demonstrate that ALK2 inhibition lowered hepcidin levels and improved iron homeostasis in preclini
Read more →KROSKeros Therapeutics to Present at the Jefferies Virtual Healthcare Conference Lexington, Massachusetts
Keros Therapeutics to Present at the Jefferies Virtual Healthcare Conference Lexington, Massachusetts - May 27, 2021 - Keros Therapeutics, Inc. ("Keros") (Nasdaq KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of nove
Read more →KROSKeros Therapeutics Announces Issuance of U.S. Patent for Use of Therapeutic Proteins in Treatment of Musculoskeletal Disorders Lexington, Mass.
Keros Therapeutics Announces Issuance of U.S. Patent for Use of Therapeutic Proteins in Treatment of Musculoskeletal Disorders Lexington, Mass. - May 25, 2021 - Keros Therapeutics, Inc. ("Keros") (Nasdaq KROS), a clinical-stage biopharmaceutical company focused on the discovery,
Read more →KROSKeros Therapeutics Presents Results from Preclinical Study of KER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference Lexington, Mass.
Keros Therapeutics Presents Results from Preclinical Study of KER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference Lexington, Mass. - May 14, 2021 - Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq KROS), a clinical-stag
Read more →KROSKeros Therapeutics to Present at the Virtual 26th Annual Congress of the European Hematology Association Lexington, Massachusetts
Keros Therapeutics to Present at the Virtual 26th Annual Congress of the European Hematology Association Lexington, Massachusetts - May 12, 2021 - Keros Therapeutics, Inc. ("Keros") (Nasdaq KROS), a clinical-stage biopharmaceutical company focused on the discovery, development a
Read more →KROSKeros Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results Lexington, Massachusetts
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results Lexington, Massachusetts - May 6, 2021 - Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq KROS), a clinical-stage biopharmaceutical company focused on the discovery, develop
Read more →KROSKeros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results Lexington, Massachusetts
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results Lexington, Massachusetts - March 25, 2021 - Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq KROS), a clinical-stage biopharmaceutical company focused on the
Read more →KROSKeros Therapeutics Presents Results from Preclinical Studies of KER-050 and ALK2 Inhibitors at the European School of Haematology (ESH) 2 nd Translational Research E-Conference Lexington, Mass.
Keros Therapeutics Presents Results from Preclinical Studies of KER-050 and ALK2 Inhibitors at the European School of Haematology (ESH) 2nd Translational Research E-Conference Lexington, Mass. - March 5, 2021 - Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq KROS), a
Read more →KROSKeros Therapeutics to Present at the H.C. Wainwright Global Life Sciences 2021 Virtual Conference Lexington, Massachusetts
Keros Therapeutics to Present at the H.C. Wainwright Global Life Sciences 2021 Virtual Conference Lexington, Massachusetts - March 2, 2021 - Keros Therapeutics, Inc. ("Keros") (Nasdaq KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and com
Read more →KROSKeros Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
LEXINGTON, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculos
Read more →KROSKeros Therapeutics to Present at the 10 th Annual SVB Leerink Global Healthcare Conference Lexington, Massachusetts
Keros Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference Lexington, Massachusetts - February 17, 2021 - Keros Therapeutics, Inc. ("Keros") (Nasdaq KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerc
Read more →KROSKeros Therapeutics Announces Addition to NASDAQ Biotechnology Index Lexington, Massachusetts
Keros Therapeutics Announces Addition to NASDAQ Biotechnology Index Lexington, Massachusetts - December 21, 2020 - Keros Therapeutics, Inc. ("Keros") (Nasdaq KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel tr
Read more →KROSKeros Therapeutics Appoints Mary Ann Gray, Ph.D., to its Board of Directors Lexington, Massachusetts
Keros Therapeutics Appoints Mary Ann Gray, Ph.D., to its Board of Directors Lexington, Massachusetts - December 17, 2020 - Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and comm
Read more →KROSKeros Therapeutics Presents Clinical Trial and Preclinical Study Results from its ALK2 Inhibitor Program, Including KER-047 Phase 1 Data, and KER-050 Preclinical Data, at the Virtual 62 nd American Society of Hematology
Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its ALK2 Inhibitor Program, Including KER-047 Phase 1 Data, and KER-050 Preclinical Data, at the Virtual 62nd American Society of Hematology Annual Meeting and Exposition Presentation highlights data f
Read more →KROSKeros Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares Lexington, Massachusetts
Keros Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares Lexington, Massachusetts - November 17, 2020 - Keros Therapeutics, Inc. ("Keros") (Nasdaq KROS), a clinical-stage biopharmaceutical com
Read more →KROSKeros Therapeutics to Present at the Jefferies Virtual London Healthcare Conference
LEXINGTON, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculos
Read more →KROSKeros Therapeutics Announces Pricing of Public Offering of Common Stock Lexington, Massachusetts
Keros Therapeutics Announces Pricing of Public Offering of Common Stock Lexington, Massachusetts - November 12, 2020 - Keros Therapeutics, Inc. ("Keros") (Nasdaq KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of nove
Read more →KROSKeros Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial Results Lexington, Massachusetts
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial Results Lexington, Massachusetts - November 10, 2020 - Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq KROS), a clinical-stage biopharmaceutical company focused on the discovery, d
Read more →KROSKeros Therapeutics to Present at the Virtual 62nd American Society of Hematology Annual Meeting and Exposition
LEXINGTON, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculos
Read more →KROSBUSINESS Overview We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders
We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. We are a leader in understanding the role of the
Read more →KROSKeros Therapeutics, Inc. Announces Dosing of First Participants in Phase 2 Clinical Trial of KER-050 in Myelodysplastic Syndromes (MDS) First two participants dosed in a Phase 2 clinical trial of KER-050 in MDS Initial d
Keros Therapeutics, Inc. Announces Dosing of First Participants in Phase 2 Clinical Trial of KER-050 in Myelodysplastic Syndromes (MDS) First two participants dosed in a Phase 2 clinical trial of KER-050 in MDS Initial data expected by mid-2021 Lexington, Massachusetts - Octob
Read more →KROSKeros Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
LEXINGTON, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculo
Read more →KROSKeros Therapeutics Presents Results from Preclinical Studies Investigating KER-012 at the American Society for Bone and Mineral Research 2020 Annual Meeting Lexington, Massachusetts
Keros Therapeutics Presents Results from Preclinical Studies Investigating KER-012 at the American Society for Bone and Mineral Research 2020 Annual Meeting Lexington, Massachusetts - September 11, 2020 - Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq KROS), a clini
Read more →KROSKeros Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial Results Lexington, Massachusetts
Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial Results Lexington, Massachusetts - August 13, 2020 - Keros Therapeutics, Inc. ("Keros") (Nasdaq KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and com
Read more →KROSKeros Therapeutics to be Featured on The Balancing Act's "Behind the Mystery" Rare Disease Series
LEXINGTON, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematolog
Read more →KROSKeros Therapeutics, Inc. Announces Completion of Dosing of Planned Cohorts in KER-047 Phase 1 Trial and Provides Program Update Lexington, Massachusetts
Keros Therapeutics, Inc. Announces Completion of Dosing of Planned Cohorts in KER-047 Phase 1 Trial and Provides Program Update Lexington, Massachusetts - August 4, 2020 - Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq KROS), a clinical-stage biopharmaceutical compa
Read more →KROSKeros Therapeutics Set to Join Russell 2000 Index Lexington, Massachusetts
Keros Therapeutics Set to Join Russell 2000 Index Lexington, Massachusetts - June 26, 2020 - Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatme
Read more →KROSKeros Therapeutics Set to Join Russell 2000 Index
LEXINGTON, Mass, June 26, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologi
Read more →KROSKeros Therapeutics Presents Results from Clinical and Preclinical Studies Investigating KER-050, along with Preclinical Data from its ALK2 Inhibitor Program, at the European Hematology Association 2020 Annual Meeting Pos
Keros Therapeutics Presents Results from Clinical and Preclinical Studies Investigating KER-050, along with Preclinical Data from its ALK2 Inhibitor Program, at the European Hematology Association 2020 Annual Meeting Poster presentation highlights Phase 1 clinical trial data dem
Read more →KROSKeros Therapeutics To Present At The Jefferies 2020 Virtual Healthcare Conference
LEXINGTON, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculosk
Read more →KROSKeros Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results Lexington, Massachusetts
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results Lexington, Massachusetts - May 22, 2020 - Keros Therapeutics, Inc. ("Keros") (Nasdaq KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerc
Read more →KROSKeros Therapeutics to Present at the Virtual 25th Annual Congress of the European Hematology Association
LEXINGTON, Mass., May 14, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculosk
Read more →KROSKeros Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
LEXINGTON, Mass., April 13, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculo
Read more →KROSKeros Therapeutics Receives $23 million Series B Funding for Development of Therapies to Treat Debilitating Neuromuscular Diseases
LEXINGTON, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Keros Therapeutics, a company dedicated to the discovery and development of novel therapeutics for neuromuscular diseases, announced a $23 million Series B financing today. This investment, coupled with Series A in 2016, brings
Read more →Competitive Position
How KROS ranks across every disease it competes inCompetitive Position is a premium feature
See how KROS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial